Top

International Journal of Clinical Oncology

Published in:

01-08-2010 | Original Article

Endometrial carcinoma: better prognosis for asymptomatic recurrences than for symptomatic cases found by routine follow-up

Authors: Yutaka Ueda, Takayuki Enomoto, Tomomi Egawa-Takata, Takashi Miyatake, Kiyoshi Yoshino, Masami Fujita, Shinya Matsuzaki, Takuhei Yokoyama, Yukari Miyoshi, Tadashi Kimura

Published in: International Journal of Clinical Oncology | Issue 4/2010

Abstract

Background

The aim of this study was to determine if there is a prognostic value for the presence of symptoms at the time of recurrence detection in surgically resected endometrial carcinoma patients.

Methods

During the study period of 2000–2006, complete surgical removal of endometrial carcinoma was achieved in 271 stage I–IV endometrial cancer cases at the Department of Obstetrics and Gynecology of Osaka University Hospital, Osaka, Japan. A subsequent recurrence was detected in 29 (11%) of these cases. Patient characteristics and clinicopathological features were retrospectively reviewed utilizing their clinical records.

Results

Among the 29 cases with a recurrence, 13 (45%) had symptoms, whereas in the other 16 cases (55%) the recurrent disease was found only during routine follow-up procedures. Although the time to detection of recurrence was similar for both asymptomatic and symptomatic cases, progression-free survival after detection in the 16 asymptomatic patients was significantly longer than for the 13 symptomatic patients (P = 0.017); this was found to be especially true in those who underwent chemotherapy as their adjuvant therapy (P = 0.023).

Conclusions

A better prognosis after recurrence was demonstrated in cases that were asymptomatic at the time of recurrence detection than in those in which the tumor was symptomatic. This finding implies that, after the initial surgical resection, intensive follow-up intervention looking for asymptomatic recurrences may significantly improve the prognosis of endometrial carcinoma patients. A further in-depth prospective study is required to establish a standard strategy of follow-up care for endometrial cancer patients.

DiSaia PJ, Creasman WT (2002) Clinical gynecologic oncology, 6th edn. St. Louis, Mosby

Morice P, Levy-Piedbois C, Ajaj S et al (2001) Value and cost evaluation of routine follow-up for patients with clinical stage I/II endometrial cancer. Eur J Cancer 37:985–990CrossRefPubMed

Owen P, Duncan ID (1996) Is there any value in the long term follow up of women treated for endometrial cancer? Br J Obstet Gynaecol 103:710–713PubMed

Gadducci A, Cosio S, Fanucchi A et al (2000) An intensive follow-up does not change survival of patients with clinical stage I endometrial cancer. Anticancer Res 20:1977–1984PubMed

Agboola OO, Grunfeld E, Coyle D et al (1997) Costs and benefits of routine follow-up after curative treatment for endometrial cancer. Can Med Assoc J 157:879–886

Gordon AF, Owen P, Chien PF et al (1997) A critical evaluation of follow-up of women treated for endometrial adenocarcinoma. J Obstet Gynaecol 17:386–389CrossRefPubMed

Ng TY, Ngan HY, Cheng DK et al (1997) Vaginal vault cytology in the routine follow-up of patients treated for endometrial carcinoma: is it useful? Aust N Z J Obstet Gynaecol 37:104–106CrossRefPubMed

Salvesen HB, Akslen LA, Iversen T et al (1997) Recurrence of endometrial carcinoma and the value of routine follow up. Br J Obstet Gynaecol 104:1302–1307PubMed

Berchuck A, Anspach C, Evans AC et al (1995) Postsurgical surveillance of patients with FIGO stage I/II endometrial adenocarcinoma. Gynecol Oncol 59:20–24CrossRefPubMed

10.

Reddoch JM, Burke TW, Morris M et al (1995) Surveillance for recurrent endometrial carcinoma: development of a follow-up scheme. Gynecol Oncol 59:221–225CrossRefPubMed

11.

Shumsky AG, Stuart GC, Brasher PM et al (1994) An evaluation of routine follow-up of patients treated for endometrial carcinoma. Gynecol Oncol 55:229–233CrossRefPubMed

12.

Podczaski E, Kaminski P, Gurski K et al (1992) Detection and patterns of treatment failure in 300 consecutive cases of “early” endometrial cancer after primary surgery. Gynecol Oncol 47:323–327CrossRefPubMed

13.

MacDonald JH, Kidd GM (1990) An audit of endometrial carcinoma: the value of routine follow up. J Obstet Gynaecol 10:548–550CrossRef

14.

Fung-Kee-Fung M, Dodge J, Elit L et al (2006) Cancer Care Ontario Program in Evidence-based Care Gynecology Cancer Disease Site Group Follow-up after primary therapy for endometrial cancer: a systematic review. Gynecol Oncol 10:520–529CrossRef

15.

Elit L, Fyles AW, Devries MC et al (2009) Follow-up for women after treatment for cervical cancer: a systematic review. Gynecol Oncol 114:528–535CrossRefPubMed

16.

Randall ME, Filiaci VL, Muss H et al (2006) Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 24:36–44CrossRefPubMed

17.

Keys HM, Roberts JA, Brunetto VL et al (2004) A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 92:744–751CrossRefPubMed

18.

Creutzberg CL, van Putten WL, Koper PC et al (2000) Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomized trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma. Lancet 355:1404–1411CrossRefPubMed

19.

Aalders J, Abeler V, Kolstad P et al (1980) Postoperative external irradiation and prognostic parameters in stage I endometrial carcinoma: clinical and histopathologic study of 540 patients. Obstet Gynecol 56:419–427PubMed

20.

Piver MS, Yazigi R, Blumenson L et al (1979) A prospective trail comparing hysterectomy, hysterectomy plus vaginal radium, and uterine radium plus hysterectomy in stage I endometrial carcinoma. Obstet Gynecol 54:85–89CrossRefPubMed

Title: Endometrial carcinoma: better prognosis for asymptomatic recurrences than for symptomatic cases found by routine follow-up
Authors: Yutaka Ueda
Takayuki Enomoto
Tomomi Egawa-Takata
Takashi Miyatake
Kiyoshi Yoshino
Masami Fujita
Shinya Matsuzaki
Takuhei Yokoyama
Yukari Miyoshi
Tadashi Kimura
Publication date: 01-08-2010
Publisher: Springer Japan
Published in: International Journal of Clinical Oncology / Issue 4/2010
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI: https://doi.org/10.1007/s10147-010-0080-7

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 4/2010

Clinicopathological features and treatment strategy for triple-negative breast cancer

Serum thymidine kinase 1 correlates to clinical stages and clinical reactions and monitors the outcome of therapy of 1,247 cancer patients in routine clinical settings

Third-line gemcitabine monotherapy for platinum-resistant advanced urothelial cancer

Treatment strategy for HER2-positive breast cancer

A case report of metastatic neuroendocrine carcinoma of the right adrenal gland successfully treated with chemotherapy and surgery

Long-term results of combined chemotherapy with gemcitabine and cisplatin for metastatic urothelial carcinomas

Keynote webinar | Spotlight on antibody–drug conjugates in cancer